TG Therapeutics, Inc. reported $800M of revenue over the trailing twelve months, +76% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $800M (to Q2 2026). Net income: $441M, trailing twelve months to Q2 2026. Free cash flow: $17M, trailing twelve months to Q2 2026. Operating margin: 18%, trailing twelve months to Q2 2026.

TGTXTG Therapeutics, Inc.

Healthcare

$55.37+71% 1Y

$55.37

$26.9452 weeks$58.12

TGTX as reported

TG Therapeutics, Inc. reported $800M of revenue over the trailing twelve months, +76% on the year before. 11 reported series are charted on this page, each one as filed.

$800M

Revenue, trailing twelve months · to Q2 2026 · +76% against the twelve months before

Net income: $441M
Net income · +630% year on year · trailing twelve months to Q2 2026
Free cash flow: $17M
Free cash flow · −129% year on year · trailing twelve months to Q2 2026
Operating margin: 18%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TGTX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$800M	+76%	Q2 2026
Net income	$441M	+630%	Q2 2026
EPS	$2.75	+643%	Q2 2026
Gross margin	82%	n/a	Q2 2026
Operating margin	18%	n/a	Q2 2026
Net margin	67%	n/a	Q2 2026
ROE	74%	n/a	Q2 2026
ROA	36%	n/a	Q2 2026
ROIC	13%	n/a	Q2 2026
Free cash flow	$17M	−129%	Q2 2026
P/E	20.1	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.